Zacks: Brokerages expect Fortress Biotech, Inc. (NASDAQ:FBIO) to post earnings per share of -$0.21

Wall Street brokers expect Fortress Biotech, Inc. (NASDAQ:FBIO – Get Rating) to report earnings of ($0.21) per share for the current quarter, reports Zacks Investment Research. Five analysts have made earnings estimates for Fortress Biotech. The lowest EPS estimate is ($0.37) and the highest is ($0.06). Fortress Biotech reported earnings per share of ($0.11) in the same quarter last year, suggesting a negative 90.9% year-over-year growth rate. The company is expected to release its next quarterly earnings report on Monday, January 1.

On average, analysts expect Fortress Biotech to report annual earnings of ($0.75) per share for the current year, with EPS estimates ranging from ($1.50) to ($0. $30). For next year, analysts expect the company to post earnings of $0.10 per share, with EPS estimates ranging from ($1.45) to $2.19. Zacks Investment Research earnings per share averages are an average average based on a survey of analysts who provide coverage for Fortress Biotech.

Fortress Biotech (NASDAQ:FBIO – Get Rating) last reported results on Monday, March 28. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analyst consensus estimates of $0.08 per ($0.46). Fortress Biotech had a negative return on equity of 27.80% and a negative net margin of 94.06%.

A number of brokerages have recently commented on FBIO. TheStreet downgraded shares of Fortress Biotech from a “c-” rating to a “d+” rating in a Monday, February 14, report. StockNews.com upgraded shares of Fortress Biotech from a “sell” rating to a “hold” rating in a research report on Monday. Roth Capital reaffirmed a “buy” rating on Fortress Biotech shares in a Tuesday, March 29 research report. Finally, Zacks Investment Research moved shares of Fortress Biotech from a “hold” rating to a “strong sell” rating in a Thursday, March 31 research report. One analyst rated the stock with a sell rating, one gave the stock a hold rating, and four gave the stock a buy rating. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $10.38.

Shares on the NASDAQ FBIO traded down $0.04 at midday Tuesday, hitting $1.02. 3,633 shares of the company were traded, with an average volume of 519,445. The stock’s 50-day moving average price is $1.39 and its 200-day moving average price is $2.23. The stock has a market capitalization of $106.59 million, a P/E ratio of -1.29 and a beta of 2.29. Fortress Biotech has a 1-year low of $1.02 and a 1-year high of $4.79. The company has a quick ratio of 3.33, a current ratio of 3.43 and a leverage ratio of 0.21.

Hedge funds have recently increased or reduced their stakes in the company. Citigroup Inc. increased its position in Fortress Biotech shares by 160.5% during the third quarter. Citigroup Inc. now owns 8,879 shares of the biopharmaceutical company worth $29,000 after buying an additional 5,470 shares last quarter. Marshall Wace LLP bought a new stock position in Fortress Biotech during Q4 for a value of approximately $30,000. Two Sigma Securities LLC purchased a new stock position in Fortress Biotech during Q3 for a value of approximately $33,000. BNP Paribas Arbitrage SA increased its position in Fortress Biotech shares by 319.9% ​​in the third quarter. BNP Paribas Arbitrage SA now owns 12,459 shares of the biopharmaceutical company worth $40,000 after buying an additional 9,492 shares last quarter. Finally, ProShare Advisors LLC purchased a new position in Fortress Biotech stock during Q4 worth approximately $41,000. 30.77% of the shares are currently held by institutional investors.

About Fortress Biotech (Get an assessment)

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of moderate to severe non-nodular acne vulgaris; Targadox for severe acne; Exelderm cream for symptoms of ringworm and jock itch; Ceracade for dry skin; Luxamend for dressing and treating wounds; and Accutane capsules for severe recalcitrant nodular acne.

See also

Get a Free Copy of Zacks’ Research Report on Fortress Biotech (FBIO)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for Fortress Biotech (NASDAQ:FBIO)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Fortress Biotech right now?

Before you consider Fortress Biotech, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Fortress Biotech wasn’t on the list.

Although Fortress Biotech currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

About Sally Dominguez

Check Also

This Clinique Overnight Mask Improved My Skin the First Time I Used It – E! On line

If you need more information before you shop, check out these rave reviews from Sephora …